Infliximab biosimilar - Reliance Life Sciences

Drug Profile

Infliximab biosimilar - Reliance Life Sciences

Alternative Names: BOW-015; Infimab; R-TPR-015

Latest Information Update: 01 Aug 2016

Price : $50

At a glance

  • Originator EPIRUS Biopharmaceuticals
  • Developer EPIRUS Biopharmaceuticals; Sun Pharmaceutical Industries
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Rheumatoid arthritis

Highest Development Phases

  • Marketed Rheumatoid arthritis
  • Preregistration Autoimmune disorders

Most Recent Events

  • 25 Jul 2016 EPIRUS Biopharmaceuticals files for Chapter 7 bankruptcy (Epirus Biopharmaceuticals 8-K, July 2016)
  • 18 Jul 2016 Reliance Life Sciences acquires Infliximab biosimilar from EPIRUS Biopharmaceuticals (Epirus Biopharmaceuticals 8-K, July 2016)
  • 09 May 2016 Infliximab biosimilar - EPIRUS Biopharmaceuticals is available for licensing in USA, Latin America, Europe as of 09 May 2016. http://www.epirusbiopharma.com/index.php
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top